🔍

CAPLIPOINT - Caplin Point Lab

📊 NSE: CAPLIPOINT 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 20:42

📢 Recent Corporate Announcements

Caplin Point Subsidiary Gets USFDA Approval for Potassium Phosphates Injection ($57M Market)

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 13 Mar 2026, 12:03 PM

Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Potassium Phosphates Injection USP, a generic version of Fresenius Kabi's reference drug. The product is used to treat hypophosphatemia and as parenteral nutrition for patients who cannot take oral supplements. According to IQVIA data, the addressable US market for this product was approximately $57 million for the 12-month period ending January 2026. This approval marks the 53rd for the subsidiary, which maintains a high success rate with 53 approvals out of 54 ANDAs filed.

Final USFDA approval received for Potassium Phosphates Injection USP in 5 mL, 15 mL, and 50 mL vials.
Addressable US market size for the product is approximately $57 million as of January 2026.
Caplin Steriles has now secured 53 approvals out of 54 ANDAs filed in the US market.
The company is currently working on a pipeline of 55+ simple and complex injectable and ophthalmic products.
Product serves a critical medical need for parenteral nutrition in both adult and pediatric patients.

💡 This approval strengthens Caplin Point's US portfolio and provides a clear revenue growth path in the sterile injectables segment. Investors should monitor the company's execution in capturing market share within this $57 million segment and the progress of its extensive 55+ product pipeline.

Caplin Point Subsidiary Gets USFDA Approval for Desmopressin Acetate Injection

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 28 Feb 2026, 11:57 AM

Caplin Point's subsidiary, Caplin Steriles, has received final USFDA approval for Desmopressin Acetate Injection USP, a generic version of Nordic Pharma's DDAVP. The injection is used to treat haemophilia A and diabetes insipidus, targeting a US market valued at approximately $26 million as of December 2025. This approval brings the subsidiary's total USFDA approvals to 52 out of 54 ANDAs filed, showcasing a robust regulatory track record. The company maintains a strong pipeline with over 55 products planned for filing in the next four years.

Final USFDA approval received for Desmopressin Acetate Injection USP in single and multi-dose vials.
Target US market size for the product is approximately $26 million for the 12-month period ending December 2025.
Caplin Steriles has now achieved 52 approvals out of 54 ANDAs filed in the US market.
Company pipeline includes 55+ simple and complex injectable and ophthalmic products for the next 4 years.

💡 Investors should monitor the commercial rollout of this product as it adds to the company's growing US injectable portfolio. The high approval-to-filing ratio reflects strong execution capabilities in the regulated US market.

Caplin Point Subsidiary Receives USFDA Approval for Sodium Phosphates Injection ($67M Market)

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 24 Feb 2026, 12:40 PM

Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Sodium Phosphates Injection USP, a generic equivalent of Hospira's reference drug. The product is used to treat hypophosphatemia and addresses a US market estimated at approximately $67 million for the 12-month period ending December 2025. This approval brings the subsidiary's total USFDA approvals to 51 out of 54 ANDAs filed, highlighting a strong regulatory track record. The company is actively developing a pipeline of over 55 additional injectable and ophthalmic products for future filings.

Final USFDA approval received for Sodium Phosphates Injection USP in three vial sizes (5mL, 15mL, and 50mL).
Target US market size for this product is approximately $67 million as of December 2025 per IQVIA data.
Caplin Steriles has achieved 51 approvals out of 54 ANDAs filed to date in the US market.
The company has a robust pipeline of 55+ simple and complex injectable and ophthalmic products planned for the next 4 years.

💡 Investors should view this as a positive expansion of Caplin's US sterile injectable portfolio, which is a high-margin segment. Monitor the company's ability to convert these approvals into market share and revenue growth in the upcoming quarters.

Caplin Point Laboratories Releases Q3 FY26 Earnings Call Transcript

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 09:39 PM

Caplin Point Laboratories has released the official transcript of its Q3 FY 2025-26 earnings call, which was held on February 5, 2026. The transcript details the company's financial performance for the quarter and the nine-month period ending December 31, 2025. This disclosure is a standard regulatory requirement under SEBI LODR to provide transparency regarding management's interaction with analysts. Investors can access the full text on the company's website to review specific management commentary on growth drivers.

Transcript for the Q3 FY26 earnings call held on February 5, 2026, is now publicly available.
Covers financial performance and management outlook for the nine-month period ended December 31, 2025.
Filing made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The document provides a verbatim record of the Q&A session between institutional investors and company management.

💡 Investors should review the transcript for qualitative insights into the company's Latin American operations and US market expansion plans. No immediate trading action is required based on this routine administrative filing.

Caplin Point Laboratories Releases Q3 FY 2025-26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 05 Feb 2026, 09:35 PM

Caplin Point Laboratories has officially released the audio recording of its Q3 FY 2025-26 earnings conference call held on February 05, 2026. This disclosure follows the company's earlier announcement on January 29, 2026, regarding the scheduled financial results discussion. The recording provides investors with direct access to management's commentary on the quarter's performance and strategic outlook. Such recordings are essential for shareholders to understand the qualitative aspects of the company's growth trajectory and operational challenges.

Audio recording of the Q3 FY 2025-26 earnings call is now available on the company's website.
The earnings call was conducted on February 05, 2026, at 16:00 hrs IST.
The filing is a routine regulatory update in compliance with SEBI (LODR) Regulations.
Investors can access the link provided in the disclosure to hear management's detailed Q&A session.

💡 Investors should review the audio recording to gain insights into management's guidance on Latin American market stability and US business expansion. Focus on commentary regarding R&D spending and any updates on new product launches.

Caplin Point Q3 Standalone Net Profit Grows 16.8% YoY to ₹87.28 Cr; Revenue Up 2.1%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 02:40 PM

Caplin Point Laboratories reported a standalone net profit of ₹87.28 crore for the quarter ended December 31, 2025, marking a 16.8% increase over the ₹74.71 crore reported in the same period last year. Revenue from operations saw a modest growth of 2.1% YoY, reaching ₹189.22 crore. For the nine-month period (9M FY26), standalone net profit rose to ₹275.79 crore from ₹252.99 crore in 9M FY25. The company maintained strong profitability despite a slight sequential dip in revenue and profit compared to Q2 FY26.

Standalone Net Profit increased 16.8% YoY to ₹87.28 crore in Q3 FY26.
Revenue from operations grew slightly to ₹189.22 crore from ₹185.23 crore in Q3 FY25.
9M FY26 Standalone Net Profit reached ₹275.79 crore, showing steady growth from ₹252.99 crore YoY.
Total expenses for the quarter were reduced to ₹103.94 crore from ₹113.89 crore in the previous year's quarter.
A minor impact of ₹0.84 crore was recognized due to the implementation of new Labour Codes.

💡 The company shows strong bottom-line growth on a standalone basis, driven by effective cost control. Investors should hold for long-term growth but wait for the full consolidated presentation to assess the performance of international subsidiaries.

Caplin Point Q3 Standalone Net Profit Up 16.8% YoY to ₹87.28 Cr; Revenue at ₹189.22 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 01:14 PM

Caplin Point Laboratories reported a steady standalone performance for Q3 FY26, with revenue from operations growing 2.15% YoY to ₹189.22 crore. Standalone net profit saw a robust 16.8% YoY increase to ₹87.28 crore, supported by a reduction in total expenses from ₹113.89 crore to ₹103.94 crore. While sequential profit declined from ₹102.59 crore in Q2 FY26, this was largely due to a ₹23.63 crore dividend from a subsidiary recorded in the previous quarter. The company also successfully integrated a ₹0.84 crore impact from new labor code provisions during this period.

Standalone Revenue from operations rose to ₹189.22 crore in Q3 FY26 compared to ₹185.23 crore in Q3 FY25.
Standalone Net Profit increased 16.8% YoY to ₹87.28 crore, with Basic EPS rising to ₹11.49 from ₹9.83.
Total Standalone Expenses decreased to ₹103.94 crore from ₹113.89 crore in the corresponding quarter last year.
Profit Before Tax (PBT) stood at ₹117.01 crore, reflecting improved operational margins YoY.
A one-time impact of ₹0.84 crore was recorded due to the notification of New Labour Codes effective November 2025.

💡 Investors should view the YoY growth in standalone profitability as a positive sign of operational efficiency, though the consolidated results remain the primary driver for this global pharma player. Maintain a long-term perspective while monitoring the scale-up of US and emerging market subsidiaries.

Caplin Point Appoints Two Vice-Chairmen and Retired IAS Officer to Board

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 03 Feb 2026, 03:24 PM

Caplin Point Laboratories has received shareholder approval for the appointment of four directors following a postal ballot on January 31, 2026. Mr. Ashok Partheeban and Mr. Vivek Partheeban have been appointed as Vice-Chairmen of the company. Additionally, the board has been strengthened with the appointment of Mrs. Susan Mathew, a retired IAS officer with 36 years of administrative experience, and Dr. K C John as Independent Directors for five-year terms. These appointments are aimed at enhancing corporate governance and strategic oversight.

Ashok Partheeban and Vivek Partheeban appointed as Vice-Chairmen effective November 5, 2025
Mrs. Susan Mathew, a 1975 batch retired IAS officer, appointed as Independent Director for 5 years
Dr. K C John appointed as Independent Director for a 5-year term starting November 5, 2025
Mrs. Susan Mathew brings over 36 years of experience, having served as Additional Chief Secretary and CMD of TIDCO
All appointments were approved by shareholders via Postal Ballot concluded on January 31, 2026

💡 Investors should view the addition of a highly experienced former bureaucrat and the formalization of leadership roles as a positive step for corporate governance. No immediate portfolio changes are necessary based on this administrative update.

Caplin Point Shareholders Approve Key Leadership and Independent Director Appointments

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 03 Feb 2026, 03:11 PM

Caplin Point Laboratories has successfully passed four key resolutions through a postal ballot as of February 3, 2026. Shareholders approved the appointments of Mr. Ashok Partheeban and Mr. Vivek Partheeban as Directors and Vice-Chairmen of the company. Furthermore, the board has been strengthened with the appointment of Dr. K C John and Mrs. Susan Mathew as Non-Executive Independent Directors for five-year terms. All resolutions were passed with the requisite majority, ensuring leadership continuity and enhanced corporate governance.

Appointment of Mr. Ashok Partheeban as Director and Vice-Chairman approved by shareholders
Appointment of Mr. Vivek Partheeban as Director and Vice-Chairman approved by shareholders
Dr. K C John appointed as Non-Executive Independent Director for a fixed term of 5 years
Mrs. Susan Mathew appointed as Non-Executive Independent Director for a fixed term of 5 years
All resolutions passed with requisite majority via remote e-voting results declared on Feb 3, 2026

💡 Investors should take note of the leadership continuity and the addition of independent oversight to the board. No immediate action is required as these appointments align with standard corporate governance practices.

Caplin Point Laboratories to Host Q3 FY26 Earnings Call on February 5, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jan 2026, 04:04 PM

Caplin Point Laboratories has scheduled its post-results conference call for February 5, 2026, at 4:00 PM IST. The management team, including the Chairman and Managing Director, will discuss the company's financial performance for the quarter ended December 31, 2025. This call is a standard procedure following the release of quarterly financial results to engage with analysts and institutional investors. Investors can join the session via the provided DiamondPass link or universal dial-in numbers.

Earnings conference call scheduled for February 5, 2026, at 16:00 hrs IST.
Management representation includes the Chairman, Vice Chairman, Managing Director, and CFO.
Focus will be on the financial performance for the quarter ended December 31, 2025 (Q3 FY26).
Universal dial-in numbers for the call are +91 22 6280 1116 and +91 22 7115 8017.

💡 Investors should review the Q3 FY26 financial results once released and participate in the call to understand management's outlook on the US and Latin American markets.

Caplin Point Subsidiary Gets USFDA Approval for Generic Depo-Medrol; $57.4M Market Opportunity

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 27 Jan 2026, 04:03 PM

Caplin Point's subsidiary, Caplin Steriles, has secured final USFDA approval for Methylprednisolone Acetate Injectable Suspension, a generic version of Pfizer's Depo-Medrol. The product addresses a US market valued at approximately $57.4 million for the 12 months ending November 2025. This approval brings the subsidiary's total USFDA approvals to 50 out of 53 filings. The company continues to build a strong pipeline with over 55 injectable and ophthalmic products currently under development for the next four years.

Final USFDA approval received for Methylprednisolone Acetate Injectable (40mg/mL & 80mg/mL).
Addresses a US market opportunity of approximately $57.4 million annually as per IQVIA data.
Milestone 50th approval for subsidiary Caplin Steriles Limited out of 53 ANDA filings.
Strong future pipeline with 55+ simple and complex injectable products in development.

💡 This approval reinforces Caplin Point's execution capabilities in the high-margin sterile injectables space. Investors should monitor the commercial launch and subsequent market share capture in the US.

Caplin Point Complies with SEBI Dematerialization Norms for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 14 Jan 2026, 11:06 AM

Caplin Point Laboratories has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Integrated Registry Management Services, confirms that all dematerialization requests received during the quarter ended December 31, 2025, were processed correctly. It ensures that physical share certificates were cancelled and the names of depositories were updated in the company's records within the mandated 15-day timeframe. This is a standard administrative procedure to maintain transparency in shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025
Confirmation that dematerialization requests were processed within 15 days of receipt
Physical certificates were mutilated and cancelled after verification by the depository participant
Registrar and Transfer Agent (RTA) is Integrated Registry Management Services Private Limited

💡 No action is required as this is a routine regulatory filing confirming administrative compliance. Investors should focus on upcoming earnings or business expansion news for price-moving triggers.

Caplin Point Acquires 10 Approved ANDAs with $473.2 Million Addressable Market

🟢 POSITIVE ⭐ 8/10

M&A 📅 01 Jan 2026, 11:34 AM

Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) from a leading multinational generic company. The acquired portfolio focuses on Injectable and Ophthalmic products, which had an addressable market of $473.2 million for the 12-month period ending August 2025. This acquisition includes oncology injectables that will be manufactured at the company's new dedicated facility in Kakkalur. The company plans to commercialize these products in the U.S. and progressively expand into Mexico, Canada, the EU, and Brazil.

Acquisition of 10 approved ANDAs for Injectable and Ophthalmic products from a major MNC
Addressable market for the acquired products valued at $473.2 million as of August 2025
Caplin Steriles now has 49 approvals out of 53 ANDA filings in the USA
Includes oncology injectables to be commercialized from the new dedicated Kakkalur facility
Strategic expansion planned for regulated markets including Canada, EU, and Brazil

💡 This acquisition is a significant positive as it provides immediate access to approved products in high-value segments, bypassing long R&D and approval cycles. Investors should monitor the commercialization timeline and the resulting revenue growth in the U.S. and other regulated markets.

Caplin Point Laboratories Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Dec 2025, 06:24 PM

Caplin Point Laboratories Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This move is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure is specifically linked to the finalization and upcoming declaration of the company's unaudited financial results for the quarter ending December 31, 2025. The trading window will remain closed until 48 hours after the financial results are officially released to the stock exchanges.

Trading window closure effective from January 1, 2026.
Closure is in connection with the Q3 financial results for the period ending December 31, 2025.
Window to reopen 48 hours after the official declaration of financial results.
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct.

💡 This is a routine regulatory announcement with no immediate impact on stock fundamentals. Investors should look forward to the upcoming quarterly earnings release for actual performance data.

Caplin Point Seeks Approval for Appointment of Vice-Chairmen and Independent Directors

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 31 Dec 2025, 03:15 PM

Caplin Point Laboratories has initiated a postal ballot to obtain shareholder approval for several key board appointments. The company proposes appointing Mr. Ashok Partheeban and Mr. Vivek Partheeban as Directors and Vice-Chairmen to provide strategic guidance. Furthermore, Dr. K C John and Mrs. Susan Mathew are nominated as Independent Directors for five-year tenures, despite both reaching the age of 75 during their terms. The e-voting window for these resolutions is open from January 2, 2026, until January 31, 2026.

Appointment of two new Vice-Chairmen, Mr. Ashok Partheeban and Mr. Vivek Partheeban, effective Nov 5, 2025
Nomination of Dr. K C John as Independent Director for a 5-year term starting November 2025
Nomination of Mrs. Susan Mathew as Independent Director for a 5-year term starting January 2026
E-voting period scheduled for 30 days from Jan 2 to Jan 31, 2026, for all eligible shareholders

💡 Monitor the transition in leadership as the new Vice-Chairmen take on strategic roles. Shareholders should exercise their voting rights during the January 2026 window.

View All CAPLIPOINT Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total consolidated revenue grew 15.5% YoY to INR 2,034 Cr in FY25. Revenue from operations increased 14.4% to INR 1,937.47 Cr. The US front-end entity generated initial revenue of $3.2 million (approx. INR 26.8 Cr) within its first 8 months of operation.

Geographic Revenue Split

Predominantly focused on emerging markets of Latin America (LATAM) and Africa. The company is expanding into regulated markets, with the US front-end showing early success and future revenue expected from Canada, Mexico, and Australia in FY26–27.

Profitability Margins

Gross Profit grew 20.3% to INR 1,167 Cr. Operating Profit Margin stood at 49.81% (consolidated), while Net Profit Margin improved to 27.93% in FY25 from 27.24% in FY24.

EBITDA Margin

EBITDA grew 20.2% YoY to INR 743 Cr, representing an EBITDA margin of 38.3% on revenue from operations, up from 36.5% in FY24.

Capital Expenditure

The company acquired 5.5 acres of land in Mexico for INR 19.85 Cr (USD 2.237 million) and plans to invest up to INR 133 Cr (USD 15 million) in a new manufacturing facility targeted for commissioning in FY 2027.

Credit Rating & Borrowing

The company is debt-free with a Debt-Equity Ratio listed as Not Applicable (NA). It maintains a strong cash position of INR 1,180 Cr, representing 58% of FY25 revenue.

⚙️ Operational Drivers

Raw Materials

Peptides, Key Starting Materials (KSMs) for Biosimilars, and Active Pharmaceutical Ingredients (APIs).

Import Sources

China (specifically for Peptides and KSMs) and India.

Key Suppliers

Not disclosed in available documents; referred to as quality partners in India and China.

Capacity Expansion

Mexico facility (Triwin Pharma) planned with an initial capacity of 50 million units per annum for Suppositories and Topicals by FY 2027. Current manufacturing is a mix of 60% in-house and 40% outsourced.

Raw Material Costs

Cost of Goods Sold (COGS) is approximately 39.7% of revenue (calculated from Gross Profit of INR 1,167 Cr on INR 1,937 Cr revenue). Procurement strategy focuses on asset-light outsourcing and backward integration through new API entities.

Logistics & Distribution

The company uses its own distribution networks in underserved markets to ensure faster cash cycles and receivable control.

📈 Strategic Growth

Expected Growth Rate

15.50%

Growth Strategy

Achieved through own-label front-end expansion in the US (24 products launched, 15+ more planned for FY26), greenfield expansion in Mexico (FY27), and a 'Second Innings' in China focusing on asset-light outsourcing of Peptides and Biosimilar KSMs. The company is also targeting 7 Pre-Filled Syringe filings in FY26.

Products & Services

Finished dosage forms, Injectables, Ophthalmics, RTU (Ready-to-Use) bags, Pre-filled syringes, Suppositories, and Topicals.

Brand Portfolio

Caplin Steriles (US Subsidiary), Triwin Pharma (Mexico Subsidiary).

New Products/Services

Launched RTU Bags, Ophthalmic Emulsions, and Injectable Emulsions. 15+ more products planned for US launch in FY26.

Market Expansion

Targeting Canada, Mexico, and Australia for revenue generation in FY26–27. Mexico facility targeted for FY27 commissioning.

Market Share & Ranking

Ranked on Forbes 'Asia’s 200 Best Under a Billion' list for the 7th time in 10 years.

Strategic Alliances

Collaborates with partners for ANDA filings (53 total filed with partners/acquired) and tied up with top 7 wholesalers and 24 direct buyers in the US.

🌍 External Factors

Industry Trends

Indian pharma market projected to reach $13.48bn in 2025 with a 5.31% CAGR through 2030. Shift toward complex generics, oncology drugs, and digital health innovations.

Competitive Landscape

Focuses on difficult-to-manufacture and niche products (RTU bags, pre-filled syringes) to differentiate from generic competition.

Competitive Moat

Durable advantage through own distribution networks in underserved markets and an 'always-ready' regulatory posture with USFDA, EU-GMP, and ANVISA approvals.

Macro Economic Sensitivity

Sensitive to global growth shocks and US tariff policies which are described as a 'major negative shock' to growth.

Consumer Behavior

Rising urbanization and healthcare investments in LATAM and Africa are driving increased pharmaceutical demand.

Geopolitical Risks

Exposure to political instability in LATAM and Africa; mitigated by first-mover advantage and deep market moats.

⚖️ Regulatory & Governance

Industry Regulations

Adheres to USFDA, EU-GMP, ANVISA (Brazil), and INVIMA (Colombia) standards. Maintains 'always-ready' posture to address regulatory observations swiftly.